United States
Prescription + the 503A/503B compounding framework; contested peptides sat in legal limbo until the October 30, 2026 enforcement-discretion policy — d
Prescription + the 503A/503B compounding framework; contested peptides sat in legal limbo until the October 30, 2026 enforcement-discretion policy — discretion, not authorization, and states diverge. Home market; cash-pay clinics. Full coverage in Government & The Law.
Country posture summarized from our November 7, 2026 census research (regulator-sourced where available; some country detail remains unverified and is flagged as such in the census). Global baseline: no regulator in our 28-country set has approved BPC-157 or TB-500 as a medicine.
Educational information only — not medical or legal advice. Status as of November 7, 2026. See Our Legal Mandate.